Share on StockTwits

CTI BioPharma Corp (NASDAQ:CTIC) CEO James A. Bianco unloaded 40,000 shares of CTI BioPharma Corp stock on the open market in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $2.54, for a total transaction of $101,600.00. Following the completion of the transaction, the chief executive officer now directly owns 2,257,794 shares in the company, valued at approximately $5,734,797. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on CTIC. Analysts at WallachBeth Capital upgraded shares of CTI BioPharma Corp from a “hold” rating to a “buy” rating in a research note on Tuesday, August 5th. They now have a $4.50 price target on the stock. Analysts at Ladenburg Thalmann initiated coverage on shares of CTI BioPharma Corp in a research note on Thursday, May 22nd. They set a “buy” rating and a $6.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $4.83.

CTI BioPharma Corp (NASDAQ:CTIC) traded up 1.58% during mid-day trading on Friday, hitting $2.57. 1,302,592 shares of the company’s stock traded hands. CTI BioPharma Corp has a one year low of $1.07 and a one year high of $4.25. The stock’s 50-day moving average is $2.65 and its 200-day moving average is $3.09. The company’s market cap is $371.2 million.

CTI BioPharma Corp (NASDAQ:CTIC) last released its earnings data on Monday, August 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.07. Analysts expect that CTI BioPharma Corp will post $-0.61 EPS for the current fiscal year.

CTI BioPharma Corp. (NASDAQ:CTIC), formerly Cell Therapeutics, Inc, is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.